1. Home
  2. BAH vs TGTX Comparison

BAH vs TGTX Comparison

Compare BAH & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Booz Allen Hamilton Holding Corporation

BAH

Booz Allen Hamilton Holding Corporation

N/A

Current Price

$81.48

Market Cap

9.3B

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$63.57

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BAH
TGTX
Founded
1914
1993
Country
United States
United States
Employees
31500
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.3B
8.5B
IPO Year
2010
2008

Fundamental Metrics

Financial Performance
Metric
BAH
TGTX
Price
$81.48
$63.57
Analyst Decision
Hold
Buy
Analyst Count
15
8
Target Price
★ $89.46
$69.43
AVG Volume (30 Days)
★ 2.0M
1.9M
Earning Date
10-23-2026
11-09-2026
Dividend Yield
★ 2.85%
N/A
EPS Growth
N/A
★ 1746.67
EPS
★ 3.13
0.52
Revenue
★ $11,217,000,000.00
$2,785,000.00
Revenue This Year
$1.37
$61.95
Revenue Next Year
$4.61
$35.55
P/E Ratio
★ $26.40
$124.71
Revenue Growth
★ N/A
N/A
52 Week Low
$59.50
$26.76
52 Week High
$109.10
$68.03

Technical Indicators

Market Signals
Indicator
BAH
TGTX
Relative Strength Index (RSI) 45.16 57.99
Support Level $74.35 $52.12
Resistance Level $81.76 $68.03
Average True Range (ATR) 2.91 3.49
MACD -1.00 0.09
Stochastic Oscillator 0.39 67.11

Price Performance

Historical Comparison
BAH
TGTX

About BAH Booz Allen Hamilton Holding Corporation

Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace. The domains includes Consulting Services- Delivering strategic, operational, and management consulting to transform organizations; Advanced Tech- artificial intelligence, cloud integration, and data platforms. Cybersecurity that protects critical national infrastructure, military networks, and sensitive government systems and Engineering Solutions providing mission-critical technical design and hardware integration.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: